EVOLUTION AT MERCK - INVENTING FOR LIFE

LENVIMA: POTENTIAL ACROSS BROAD RANGE OF TUMOR TYPES ⚫1L Thyroid - Approved .1L RCC Combo with Evero or KEYTRUDA (KN-581/Study 307) ⚫2L Combo with Evero (Study 205) -Approved ⚫1L (LEAP-001) .2L (Study 309 / KN-775) Endometrial carcinoma Thyroid cancer Collaboration with Eisai Renal cell carcinoma Hepatocellular carcinoma • 1L HCC Combo (LEAP-002) • 1L NSQ Combo with KEYTRUDA and Chemo (LEAP-006) •1L PD-L1+ (LEAP-007) ⚫2L NSQ (LEAP-008) ⚫1L and 2L: Planning Stages cancer Urothelial cancer Head & neck Melanoma •1L (LEAP-003) ⚫2L (LEAP-004) Basket trial Lung cancer • TNBC • Gastric •Ovarian ⚫ Colorectal ⚫1L (LEAP-011) • Glioblastoma 1L HCC Mono (Study 304) - Approved 13 trials studying KEYTRUDA in combination with Lenvima spanning >13 tumor types • Biliary MERCK INVENTING FOR LIFE # Dr. Roy Baynes H | 57

View entire presentation